title: Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray.
abstract: BACKGROUND
  Recent guidelines recommend intranasal corticosteroids as first-line treatment for managing persistent symptoms of moderate to severe allergic rhinitis (AR). However, in children, long-term continual treatment with corticosteroids has raised concerns about potential growth suppression.
  
  
  OBJECTIVE
  To evaluate the effects of the recommended once-daily dose of budesonide aqueous nasal spray on growth velocity, as measured with stadiometry, in children with perennial AR.
  
  
  METHODS
  In this double-blind, placebo-controlled, multicenter study, 229 prepubertal children (mean age, 5.9 years; age range, 4-8 years) with perennial AR were randomized (2:1) to receive budesonide aqueous nasal spray, 64 microg (32 microg per nostril) once daily, or placebo for 1 year. The change from baseline in growth velocity, height after treatment, and the percentage of patients whose percentile for height decreased from baseline to the end of treatment were evaluated.
  
  
  RESULTS
  Growth velocity was not significantly different between the 2 groups. The least-squares mean +/- SE growth velocity during treatment was 5.91 +/- 0.11 cm per year for children receiving budesonide and 6.19 +/- 0.16 cm per year for those receiving placebo. The mean difference in growth velocity between the 2 groups was 0.27 +/- 0.18 cm per year (95% confidence interval, -0.07 to 0.62 cm per year). After treatment, the mean +/- SD height was 128.8 +/- 8.7 cm for children receiving budesonide and 128.2 +/- 8.8 for those receiving placebo. The percentage of children whose percentile for height decreased during treatment was not significantly different between the 2 groups (budesonide, 59%, placebo, 54%; P = .64). The incidence and types of adverse events and the mean 24-hour urinary cortisol-creatinine ratio were similar for the 2 groups.
  
  
  CONCLUSIONS
  Treatment with budesonide aqueous nasal spray, 64 microg once daily, for 1 year did not suppress growth velocity compared with placebo and was well tolerated in prepubertal children with perennial AR.
authors.affiliation: Midwest Allergy & Asthma Clinic, Midwest Children's Chest Physicians, Omaha, Nebraska 68114, USA. murphknsc@aol.com
authors.forename: Kevin
authors.initials: K
authors.lastname: Murphy
authors.forename: Tom
authors.initials: T
authors.lastname: Uryniak
authors.forename: Brandon
authors.initials: B
authors.lastname: Simpson
authors.forename: Liza
authors.initials: L
authors.lastname: O'Dowd
mesh_terms: D000281:Administration, Intranasal; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001827:Body Height / Q000187:drug effects*; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000893:Anti-Inflammatory Agents; D019819:Budesonide